Antifungal drug response in an in vitro model of dermatophyte nail infection.
暂无分享,去创建一个
C. Osborne | N. Ryder | B. Favre | I. Leitner
[1] N. Ryder,et al. Comparison of In Vitro Activities of 17 Antifungal Drugs against a Panel of 20 Dermatophytes by Using a Microdilution Assay , 2003, Journal of Clinical Microbiology.
[2] M. Ghannoum,et al. Clinical Trichophyton rubrum Strain Exhibiting Primary Resistance to Terbinafine , 2003, Antimicrobial Agents and Chemotherapy.
[3] B. Sigurgeirsson,et al. Prevalence of onychomycosis in Iceland: a population-based study. , 2002, Acta dermato-venereologica.
[4] N. Ryder,et al. In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin. , 2002, Medical mycology.
[5] S. Stubb,et al. Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole , 2002, The British journal of dermatology.
[6] S. Veraldi,et al. Leishmaniasis of the lip. , 2002, Acta dermato-venereologica.
[7] B. Cribier,et al. Long‐term efficacy of antifungals in toenail onychomycosis: a critical review , 2001, The British journal of dermatology.
[8] J. Guarro,et al. In Vitro Activities of 10 Antifungal Drugs against 508 Dermatophyte Strains , 2001, Antimicrobial Agents and Chemotherapy.
[9] Y. Niwano,et al. Comparison of in vitro antifungal activities of topical antimycotics launched in 1990s in Japan. , 2001, International journal of antimicrobial agents.
[10] R. Summerbell,et al. Comparative efficacies of commonly used disinfectants and antifungal pharmaceutical spray preparations against dermatophytic fungi. , 2001, Medical mycology.
[11] R. Summerbell,et al. Epidemiology of Malassezia yeasts associated with pityriasis versicolor in Ontario, Canada. , 2001, Medical mycology.
[12] M. Rinaldi,et al. Comparison of In Vitro Activities of Voriconazole and Five Established Antifungal Agents against Different Species of Dermatophytes Using a Broth Macrodilution Method , 2001, Journal of Clinical Microbiology.
[13] J. Arrese,et al. A Plea to Bridge the Gap Between Antifungals and the Management of Onychomycosis , 2001, American journal of clinical dermatology.
[14] T. Takasuka. Amino acid- or protein-dependent growth of Trichophyton mentagrophytes and Trichophyton rubrum. , 2000, FEMS immunology and medical microbiology.
[15] J. Guarro,et al. In vitro Susceptibility to Itraconazole, Clotrimazole, Ketoconazole and Terbinafine of 100 Isolates of Trichophyton rubrum , 2000, Chemotherapy.
[16] B. Elewski,et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. , 2000, Journal of the American Academy of Dermatology.
[17] M. Ghannoum,et al. An evaluation of the in vitro activity of terbinafine. , 2000, Medical mycology.
[18] M. Kawai,et al. Fluorometric Assessment of In Vitro Antidermatophytic Activities of Antimycotics Based on Their Keratin-Penetrating Power , 2000, Journal of Clinical Microbiology.
[19] M. Ghannoum,et al. Antifungal Susceptibility Testing of Dermatophytes: Establishing a Medium for Inducing Conidial Growth and Evaluation of Susceptibility of Clinical Isolates , 2000, Journal of Clinical Microbiology.
[20] H. Degreef,et al. Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. , 1999, European journal of dermatology : EJD.
[21] B. Sigurgeirsson,et al. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis , 1999 .
[22] D. Strachan,et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study. , 1999, BMJ.
[23] E. Evans,et al. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. , 1999, BMJ.
[24] C. Seebacher. Grenzen der Kurzzeitbehandlung von Onychomykosen , 1998, Der Hautarzt.
[25] A. Offidani,et al. In vitro activity of terbinafine against clinical isolates of dermatophytes. , 1998, Medical mycology.
[26] E. Evans. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. , 1998, Journal of the American Academy of Dermatology.
[27] K. Hazen. Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. , 1998, Journal of the American Academy of Dermatology.
[28] H. Gugnani,et al. Keratin degradation by Scytalidium species and Fusarium solani , 1998, Mycoses.
[29] C. Seebacher. [Limits of brief treatment of onychomycoses]. , 1998, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[30] M. Richardson. Effect of Lamisil and azole antifungals in experimental nail infection. , 1997, Dermatology.
[31] T. Nishikawa,et al. Neutral red assay in minimum fungicidal concentrations of antifungal agents. , 1996, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.
[32] M. Richardson,et al. Early events in the invasion of the human nail plate by Trichophyton mentagrophytes , 1995, The British journal of dermatology.
[33] S. Stubb,et al. The prevalence of onychomycosis in Finland , 1995, The British journal of dermatology.
[34] M. Richardson,et al. Inhibitory effect of terbinafine on the invasion of nails by Trichophyton mentagrophytes. , 1995, Journal of American Academy of Dermatology.
[35] R. Summerbell,et al. The dermatophytes , 1995, Clinical microbiology reviews.
[36] Y. Clayton. Relevance of broad‐spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses , 1994, The British journal of dermatology.
[37] L. Millérioux,et al. Levels of terbinafine in plasma, stratum corneum, dermis–epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days , 1994, Clinical and experimental dermatology.
[38] L. Millérioux,et al. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. , 1993, Acta dermato-venereologica.
[39] N. Ryder,et al. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition , 1992, The British journal of dermatology.
[40] G. Petrányi,et al. Antifungal activity of the allylamine derivative terbinafine in vitro , 1987, Antimicrobial Agents and Chemotherapy.
[41] Lin Jincai,et al. The Principle of Integrating Theory with Practice Must Be Conscientiously Implemented in the Teaching of Humanities , 1986 .
[42] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.